Next Generation Immunotherapies

In R&D by Freya SmaleLeave a Comment

download, nanoparticle, next generation immunotherapies

Peter Keller, Vice President Business Development, Selecta Biosciences joined us at the World Vaccine Congress Lyon 2012 to present on Synthetic Vaccine Particle technology. This technology has been created to help maximise the potential for the use of nanoparticles in vaccines. Nanoparticles have the optimal size for recognition by the immune system:

The human immune system has evolved to recognize particles

-Viruses are nanoparticles

-Bacteria are microparticles

Selecta's immunotherapies freely flow through the lymphatic system to the lymph nodes

- Delivery of required components to the targeted immune cells

- Controlled release of immunomodulators

Why not download the full presentation and discover more about broadening your pipeline & balancing your portfolio with next generation immunotherapies:

  • Applications for Synthetic Vaccine Particle (SVP) technology
  • Selecta's portfolio strategy and resource prioritization process
  • Antigen sourcing
  • Benefits of geographical expansion of R&D operations in emerging markets
  • How to build a R&D operation in Russia

 

Download the full presentation here >

For more information about this and other topics discussed at the World Vaccine Congress Lyon, subscribe to the Vaccine Nation newsletter, or visit the event website.

For more updates on the vaccines industry, follow us on Twitter: @vaccinenation or join our LinkedIn group: Vaccine Nation

Leave a Comment

Current ye@r *